Loading ...
Sorry, an error occurred while loading the content.

More Articles-Marty

Expand Messages
  • byteme
    The Hepatitis Study Center - http://www.hepatitisstudycenter.com/ The Hepatitis Study Center is now participating in the Amgen Clinical Trial Protocol #980167,
    Message 1 of 1 , Apr 3, 2000
    • 0 Attachment
      The Hepatitis Study Center - http://www.hepatitisstudycenter.com/

      The Hepatitis Study Center is now participating in the Amgen Clinical
      Trial Protocol #980167, Multicenter Randomized Trial of 15 Mcg Infergen
      Administered Daily vs. Thrice Weekly in Patients with Chronic Hepatitis
      Who Did Not Respond to Interferon Therapy.

      Enrollment will be limited to 10 patients, and enrollment ends

      This trial is for patients with hepatitis C who have failed previous
      monotherapy with any interferon. This includes failures with any of the

      pegylated interferons (without Ribavirin).

      Those with cirrhosis are NOT excluded from the trial and may participate

      if meeting eligibility criteria otherwise.
      Other eligibility criteria include:

      Hemoglobin >/= 10 gm/dl
      Platelets >/= 75,000
      Alpha fetoprotein normal within the past year
      NO evidence of any decompensated liver disease, such as ascites,
      bleeding varices or encephalopathy

      Participants will be randomized to receive 15 mcg. Infergen at either
      daily or 3x/weekly dosing regimens;

      --for those receiving 3x/week dosing, they will continue for 48 weeks
      be stopped if virus is detectable at week 12 or 24;

      --for those randomized to daily dose, they will continue to week 24 if
      virus found at week 12. At week 24, randomization is again done to
      continue daily or reduce to 3x/week to a total of 48 weeks.

      For more specific info about this protocol, please contact me at The
      Hepatitis Study Center by email at gastro_doc@... or phone at

      Steve Bonning, PA-C
      Sr. Clinical Coordinator, The Hepatitis Study Center

      Maxim Pharmaceuticals Expands Testing of Maxamine in Hepatitis C

      SAN DIEGO---(BW HealthWire)---April 3, 2000--Maxim Pharmaceuticals
      (AMEX:MMP) (SSE:MAXM) announced the initiation of a clinical study to
      evaluate the safety of triple-drug therapy incorporating the company's
      lead drug, Maxamine(R), in patients with chronic hepatitis C infection.

      The study will evaluate the safety of treatment with Maxamine in
      combination with the immunotherapeutic agent interferon-alpha and the
      anti-viral drug ribavirin in 15 hepatitis C patients who were
      nonresponsive to prior therapy. The clinical study is being conducted at

      the Kaplan Medical Center, Israel.

      Maxim also announced that it expects to commence by mid-year a
      clinical study to evaluate the safety of Maxamine in combination with
      pegylated (sustained release) interferon for the treatment of hepatitis
      patients. Moreover, the company announced that the 24-week results from
      its 129-patient dose-ranging clinical study of Maxamine and
      interferon-alpha for the treatment of hepatitis C have been accepted for

      presentation on April 12, 2000 at the 10th International Symposium on
      Viral Hepatitis and Liver Disease sponsored by the U.S. Center for
      Control and Prevention to be held in Atlanta. All three studies are
      intended to position Maxamine for the commencement of advanced clinical
      studies in hepatitis C by the end of this year.

      "The interim results reported late last year from our ongoing Phase
      hepatitis C trial suggest that Maxamine may substantially improve the
      efficacy of interferon-alpha in the treatment of hepatitis C," said Kurt

      R. Gehlsen, Maxim's vice president, development and chief technical
      "Maxamine may have the potential to benefit a number of existing and
      proposed treatments for hepatitis C using immunotherapy, regardless of
      whether that treatment consists of interferon, pegylated interferon or
      form of interferon administered in combination with anti-viral drugs.
      These two new trials are designed to facilitate more advanced testing of

      Maxamine in combination with a broad range of complementary drugs. We
      pleased that as a result of the growing interest in Maxamine both new
      safety trials will be funded by our collaborators."

      Maxim is currently conducting a 129-patient, dose-ranging clinical
      study of the combination of Maxamine and interferon-alpha in the
      of chronic hepatitis C. This ongoing study is designed to determine the
      most appropriate dose regimen for Maxamine, and to evaluate the efficacy

      of combination immunotherapy using Maxamine in the treatment of chronic
      hepatitis C.

      In late 1999, the company reported that after 12 weeks of treatment,

      72% of the patients treated with Maxamine in combination with
      interferon-alpha attained a complete biochemical and viral response.
      Published reports suggest that no more than 20-30% of patients with
      similar profiles achieve a complete biochemical and viral response when
      treated for 12 weeks with interferon alone. Maxamine, however, is an
      investigational drug and safety and efficacy
      have not been established at this time. The 24-week clinical results
      the ongoing study have been accepted for presentation April 12, 2000 at
      the 10th International Symposium on Viral Hepatitis and Liver Disease.

      Hepatitis C

      Hepatitis C is more easily transmitted than HIV and is now the
      blood-borne infection in the United States. The U.S. Center for Disease
      Control and Prevention estimates that over 4.5 million Americans are
      infected with the hepatitis C virus. The World Health Organization and
      other sources estimate that more than 200 million people are infected

      Hepatitis is a disease characterized by inflammation of the liver
      in many cases, permanent cirrhosis (scarring) of the liver tissues and
      mortality. The cycle of disease from infection to significant liver
      can take 20 years or more. Some experts estimate that without
      improvements in treatment, deaths from hepatitis C will surpass those
      HIV. Hepatitis C is the leading cause of liver cancer and the primary
      reason for liver transplantation in many countries.

      The standard treatment for hepatitis C is interferon-alpha, an
      immunotherapeutic agent often given in combination with the anti-viral
      drug ribavirin. The majority of patients do not attain a sustained
      response with current therapies.

      Maxamine Overview

      Treatment with Maxamine is based upon the discovery of a universal
      mechanism that suppresses the capacity of the immune system to detect
      destroy tumor cells or virally infected cells in many patients with
      and chronic infectious diseases. Maxamine is designed to reverse this
      immune suppression, thereby enhancing the effectiveness of
      a class of therapies that employ the body's immune system to fight
      and certain infectious diseases.

      Maxamine protects critical immune cells and is administered in
      combination with cytokines, a class of proteins such as interleukin-2
      interferon-alpha that stimulate these same immune cells. More than 1,000

      patients have been treated in the company's completed and ongoing
      trials in advanced malignant melanoma, acute myelogenous leukemia,
      hepatitis C and renal cell carcinoma. Clinical trial results to date
      suggest that Maxamine Therapy, the administration of Maxamine in
      combination with cytokines, is a safe, at-home treatment that may
      patient survival.

      Maxim Pharmaceuticals is developing advanced drugs, therapies and
      vaccines for cancer and infectious diseases. The Company's lead drug
      candidate, Maxamine, is currently being tested in three Phase III cancer

      clinical trials in 12 countries for malignant melanoma and acute
      myelogenous leukemia. Maxim expects to file its NDA and report results
      its U.S. Phase III study of Maxamine in the treatment of malignant
      melanoma in mid 2000.

      Phase II trials of Maxamine are also underway for the treatment of
      hepatitis C and advanced renal cell carcinoma. The company is also
      developing MaxDerm(TM), for the treatment of medical conditions for
      topical therapy is appropriate such as oral mucositis, herpes, decubitus

      ulcers, shingles, burns and related conditions. The company's third
      platform technology, MaxVax(TM), now in preclinical development,
      a needle-free mucosal vaccine carrier/adjuvant system for a broad range
      infectious diseases. The company expects to commercialize its
      through a combination of in-house development and collaborative
      with pharmaceutical companies.

      This news release contains certain forward-looking statements that
      involve risks and uncertainties. Such forward-looking statements include

      statements regarding the efficacy and intended utilization of Maxamine
      the company's clinical trials. Such statements are only predictions and
      the company's actual results may differ materially from those
      in these forward-looking statements. Factors that may cause such
      differences include the risk that products that appeared promising in
      early research and clinical trials do not demonstrate efficacy in
      larger-scale clinical trials and the risk that the company will not
      approval to market its products. These factors and others are more fully

      discussed under "Risk
      Factors" and elsewhere in the company's periodic and other reports as
      filed with the Securities and Exchange Commission.

      Note: Maxamine(R), Maxamine Therapy(TM), MaxDerm(TM), MaxVax(TM),
      the Maxim logo are trademarks of the company.

      Editor's Note: This release is also available on the Internet at


      Maxim Pharmaceuticals

      Larry G. Stambaugh or Dale A. Sander,


      Burns McClellan

      Ethan Denkensohn or Justin Jackson, 212/213-0006
    Your message has been successfully submitted and would be delivered to recipients shortly.